PH12012500938A1 - Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis - Google Patents
Sphingosine 1 phosphate receptor modulators and methods of chiral synthesisInfo
- Publication number
- PH12012500938A1 PH12012500938A1 PH1/2012/500938A PH12012500938A PH12012500938A1 PH 12012500938 A1 PH12012500938 A1 PH 12012500938A1 PH 12012500938 A PH12012500938 A PH 12012500938A PH 12012500938 A1 PH12012500938 A1 PH 12012500938A1
- Authority
- PH
- Philippines
- Prior art keywords
- methods
- sphingosine
- phosphate receptor
- compounds
- chiral synthesis
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- 229940127530 Sphingosine 1-Phosphate Receptor Modulators Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 2
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26128209P | 2009-11-13 | 2009-11-13 | |
| US26247409P | 2009-11-18 | 2009-11-18 | |
| PCT/US2010/056757 WO2011060389A1 (en) | 2009-11-13 | 2010-11-15 | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12012500938A1 true PH12012500938A1 (en) | 2016-09-16 |
Family
ID=43992104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2012/500938A PH12012500938A1 (en) | 2009-11-13 | 2010-11-15 | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8357706B2 (enExample) |
| EP (1) | EP2498611B1 (enExample) |
| JP (1) | JP5988379B2 (enExample) |
| KR (1) | KR101781233B1 (enExample) |
| CN (1) | CN102724880B (enExample) |
| AU (1) | AU2010320041B2 (enExample) |
| BR (1) | BR112012011430A8 (enExample) |
| CA (1) | CA2780433C (enExample) |
| CY (1) | CY1120427T1 (enExample) |
| DK (1) | DK2498611T3 (enExample) |
| EA (1) | EA023183B1 (enExample) |
| ES (1) | ES2665461T3 (enExample) |
| HR (1) | HRP20180527T1 (enExample) |
| HU (1) | HUE036391T2 (enExample) |
| IL (1) | IL219690B (enExample) |
| LT (1) | LT2498611T (enExample) |
| MX (1) | MX2012005562A (enExample) |
| MY (1) | MY160907A (enExample) |
| NZ (1) | NZ599913A (enExample) |
| PH (1) | PH12012500938A1 (enExample) |
| PL (1) | PL2498611T3 (enExample) |
| PT (1) | PT2498611T (enExample) |
| RS (1) | RS57070B1 (enExample) |
| SI (1) | SI2498611T1 (enExample) |
| WO (1) | WO2011060389A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE054000T2 (hu) | 2009-11-13 | 2021-08-30 | Receptos Llc | Szelektív szfingozin-1-foszfát-receptor modulátorok és királis szintézis eljárások |
| ES2665461T3 (es) | 2009-11-13 | 2018-04-25 | Celgene International Ii Sàrl | Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral |
| EP2706999B1 (en) | 2011-05-13 | 2019-08-28 | Celgene International II Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| CN103251950B (zh) * | 2012-02-16 | 2018-10-02 | 中国人民解放军军事科学院军事医学研究院辐射医学研究所 | S1p受体调节剂防治肠型放射病及放射性肠炎的用途 |
| ES2641376T3 (es) * | 2012-11-16 | 2017-11-08 | F. Hoffmann-La Roche Ag | Procedimiento para la preparación de ácido 2-trifluorometilisonicotínico y ésteres |
| US9540362B2 (en) | 2013-02-20 | 2017-01-10 | Lg Life Sciences Ltd. | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
| WO2015066515A1 (en) * | 2013-11-01 | 2015-05-07 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
| HRP20221417T1 (hr) | 2015-11-13 | 2023-02-03 | Oppilan Pharma Ltd. | Heterociklički spojevi za liječenje bolesti |
| WO2017109095A1 (en) * | 2015-12-22 | 2017-06-29 | AbbVie Deutschland GmbH & Co. KG | Fused (hetero)cyclic compounds as s1p modulators |
| US20210323913A1 (en) * | 2016-04-29 | 2021-10-21 | Board Of Regents, The University Of Texas System | Sigma receptor binders |
| KR102481328B1 (ko) * | 2016-07-22 | 2022-12-26 | 메드샤인 디스커버리 아이엔씨. | S1p1 작용제 및 이의 응용 |
| CN106749213B (zh) * | 2016-11-25 | 2019-07-02 | 济南大学 | 一种具有1,2,4-恶二唑结构的吲哚衍生物及制备方法和在制备抗菌药物中的应用 |
| CN108727292A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 一种奥扎莫德及其中间体的制备方法 |
| CN108727291A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 奥扎莫德及其中间体的制备方法 |
| AR116479A1 (es) | 2018-09-25 | 2021-05-12 | Quim Sintetica S A | Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios |
| CN110256288A (zh) * | 2019-05-13 | 2019-09-20 | 苏州山青竹生物医药有限公司 | 一种制备(s)-1-氨基-2,3-二氢-1h-茚-4-甲腈的方法 |
| CN112062785B (zh) * | 2019-06-11 | 2023-06-27 | 广东东阳光药业有限公司 | 奥扎莫德及其中间体的制备方法 |
| BR112022012846A2 (pt) * | 2020-01-06 | 2022-09-06 | Arena Pharm Inc | Métodos de tratamento de condições relacionadas ao receptor s1p1 |
| EP4483960A3 (en) | 2020-02-06 | 2025-03-05 | Mitsubishi Tanabe Pharma Corporation | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome |
| US20230124301A1 (en) * | 2020-03-04 | 2023-04-20 | Helioeast Pharmaceutical Co., Ltd. | Tricyclic compounds and use thereof |
| WO2024246174A1 (en) | 2023-05-31 | 2024-12-05 | Química Sintética, S.A. | Amorphous and crystalline form of ozanimod hydrochloride |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479544A (en) | 1974-02-07 | 1977-07-13 | American Cyanamid Co | 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use |
| FR2628103B1 (fr) | 1988-03-03 | 1991-06-14 | Roussel Uclaf | Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides |
| US5039802A (en) | 1990-04-18 | 1991-08-13 | Merck & Co., Inc. | Arylation process for preparation of chiral catalysts for ketone reduction |
| EP0508425A1 (en) | 1991-04-12 | 1992-10-14 | Schering Corporation | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase |
| GB2290790A (en) * | 1994-06-30 | 1996-01-10 | Merck & Co Inc | Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes |
| WO1999037642A1 (fr) * | 1998-01-23 | 1999-07-29 | Sankyo Company, Limited | Derives de spiropiperidine |
| US20040058894A1 (en) | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
| CA2509218C (en) * | 2002-12-20 | 2010-09-07 | Merck & Co., Inc. | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists |
| EP3178816A1 (en) | 2003-04-11 | 2017-06-14 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease |
| AU2004277947A1 (en) | 2003-10-01 | 2005-04-14 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists |
| WO2005058848A1 (en) | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| AU2006245349A1 (en) | 2005-02-22 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Improved process for the synthesis of enantiomeric indanylamine derivatives |
| KR100667075B1 (ko) | 2005-07-22 | 2007-01-10 | 삼성에스디아이 주식회사 | 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치 |
| US7902336B2 (en) | 2005-12-21 | 2011-03-08 | Joseph Gabriele | Catecholamine regulated protein |
| JP2009539762A (ja) | 2006-03-13 | 2009-11-19 | ファイザー・プロダクツ・インク | Ｈ３受容体のテトラリン拮抗薬 |
| US20080009534A1 (en) * | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| JP2010513283A (ja) * | 2006-12-15 | 2010-04-30 | アボット・ラボラトリーズ | 新規なオキサジアゾール化合物 |
| WO2008143729A2 (en) | 2007-02-28 | 2008-11-27 | Rib-X Pharmaceuticals, Inc. | Macrolide compounds and methods of making and using the same |
| US20090298894A1 (en) | 2008-04-21 | 2009-12-03 | Asahi Kasei Pharma Corporation | Amino acid compounds |
| PL2913326T3 (pl) | 2008-05-14 | 2020-11-16 | The Scripps Research Institute | Nowe modulatory receptorów fosforanu sfingozyny |
| WO2011005290A1 (en) | 2009-06-23 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders |
| EP2498609B1 (en) | 2009-11-13 | 2018-04-18 | Celgene International II Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| ES2665461T3 (es) | 2009-11-13 | 2018-04-25 | Celgene International Ii Sàrl | Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral |
| HUE054000T2 (hu) | 2009-11-13 | 2021-08-30 | Receptos Llc | Szelektív szfingozin-1-foszfát-receptor modulátorok és királis szintézis eljárások |
| HK1199820A1 (en) | 2011-10-12 | 2015-07-24 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
-
2010
- 2010-11-15 ES ES10830877.6T patent/ES2665461T3/es active Active
- 2010-11-15 RS RS20180389A patent/RS57070B1/sr unknown
- 2010-11-15 JP JP2012539063A patent/JP5988379B2/ja active Active
- 2010-11-15 LT LTEP10830877.6T patent/LT2498611T/lt unknown
- 2010-11-15 EP EP10830877.6A patent/EP2498611B1/en active Active
- 2010-11-15 PH PH1/2012/500938A patent/PH12012500938A1/en unknown
- 2010-11-15 MY MYPI2012002085A patent/MY160907A/en unknown
- 2010-11-15 EA EA201290331A patent/EA023183B1/ru not_active IP Right Cessation
- 2010-11-15 PL PL10830877T patent/PL2498611T3/pl unknown
- 2010-11-15 HU HUE10830877A patent/HUE036391T2/hu unknown
- 2010-11-15 WO PCT/US2010/056757 patent/WO2011060389A1/en not_active Ceased
- 2010-11-15 KR KR1020127015219A patent/KR101781233B1/ko active Active
- 2010-11-15 DK DK10830877.6T patent/DK2498611T3/en active
- 2010-11-15 MX MX2012005562A patent/MX2012005562A/es active IP Right Grant
- 2010-11-15 HR HRP20180527TT patent/HRP20180527T1/hr unknown
- 2010-11-15 AU AU2010320041A patent/AU2010320041B2/en active Active
- 2010-11-15 CA CA2780433A patent/CA2780433C/en active Active
- 2010-11-15 CN CN201080061143.3A patent/CN102724880B/zh active Active
- 2010-11-15 US US12/946,800 patent/US8357706B2/en active Active
- 2010-11-15 PT PT108308776T patent/PT2498611T/pt unknown
- 2010-11-15 BR BR112012011430A patent/BR112012011430A8/pt not_active Application Discontinuation
- 2010-11-15 NZ NZ599913A patent/NZ599913A/en unknown
- 2010-11-15 SI SI201031665T patent/SI2498611T1/en unknown
-
2012
- 2012-05-09 IL IL219690A patent/IL219690B/en active IP Right Grant
-
2013
- 2013-01-14 US US13/740,669 patent/US20130196966A1/en not_active Abandoned
-
2015
- 2015-02-27 US US14/634,439 patent/US9394264B2/en active Active
-
2018
- 2018-04-04 CY CY20181100376T patent/CY1120427T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502708A1 (en) | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| PH12012500938A1 (en) | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| PH12012500940B1 (en) | Selective heterocyclic sphingosine 1 phosphate receptor modulators | |
| WO2012158550A3 (en) | Selective heterocyclic sphingosine 1 phosphate receptor modulators | |
| MX2013004508A (es) | Moduladores del receptor nicotinico alfa-7 para el tratamiento del dolor, un transtorno psicotico, deterioro cognitivo o enfermedad de alzheimer. | |
| EA019970B8 (ru) | Производные имидазолидиндиона | |
| MY156381A (en) | Novel modulators of sphingosine phosphate receptors | |
| EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
| MX2020012825A (es) | Compuestos multiciclicos y metodos de uso de los mismos. | |
| MX2009008099A (es) | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. | |
| MX2010002674A (es) | Moduladores de gamma secretasa. | |
| WO2009076454A3 (en) | Compounds that modulate intracellular calcium | |
| MX2018015635A (es) | Composiciones y metodos para la modulacion de division de smn2 en un sujeto. | |
| MY157445A (en) | Compounds that modulate intracellular calcium. | |
| MX2011006150A (es) | Compuestos inhibidores de cinasa. | |
| MY145070A (en) | Imidazolothiazole compounds for the treatment of disease | |
| MX2010006379A (es) | Moduladores de la secretasa gamma. | |
| MX2010005028A (es) | Moduladores de gamma secretasa. | |
| MX2010007490A (es) | Preparacion de derivados de sulfamida. | |
| MX368459B (es) | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. | |
| MX2009011421A (es) | Derivados de ftalazina e isoquinolina con actividades moduladoras del receptor de la s1p. | |
| WO2010147969A3 (en) | Gamma secretase modulators | |
| MX2010001501A (es) | Moduladores de gamma secretasa. | |
| DE602008002598D1 (en) | Cyclohexylderivate | |
| MX2011007384A (es) | Terapias de combinacion para trastornos neoplásticos. |